GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Sirio Pharma Co Ltd (SZSE:300791) » Definitions » EV-to-EBITDA

Sirio Pharma Co (SZSE:300791) EV-to-EBITDA : 18.79 (As of Jun. 19, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Sirio Pharma Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sirio Pharma Co's enterprise value is ¥7,561 Mil. Sirio Pharma Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥402 Mil. Therefore, Sirio Pharma Co's EV-to-EBITDA for today is 18.79.

The historical rank and industry rank for Sirio Pharma Co's EV-to-EBITDA or its related term are showing as below:

SZSE:300791' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.96   Med: 21.3   Max: 64.28
Current: 18.79

During the past 12 years, the highest EV-to-EBITDA of Sirio Pharma Co was 64.28. The lowest was 9.96. And the median was 21.30.

SZSE:300791's EV-to-EBITDA is ranked worse than
73.67% of 1561 companies
in the Consumer Packaged Goods industry
Industry Median: 10.77 vs SZSE:300791: 18.79

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-19), Sirio Pharma Co's stock price is ¥36.13. Sirio Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1.743. Therefore, Sirio Pharma Co's PE Ratio for today is 20.73.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Sirio Pharma Co EV-to-EBITDA Historical Data

The historical data trend for Sirio Pharma Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sirio Pharma Co EV-to-EBITDA Chart

Sirio Pharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.16 26.39 17.90 14.07 11.67

Sirio Pharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.74 20.40 16.77 11.67 18.86

Competitive Comparison of Sirio Pharma Co's EV-to-EBITDA

For the Packaged Foods subindustry, Sirio Pharma Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sirio Pharma Co's EV-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Sirio Pharma Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sirio Pharma Co's EV-to-EBITDA falls into.



Sirio Pharma Co EV-to-EBITDA Calculation

Sirio Pharma Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=7561.184/402.369
=18.79

Sirio Pharma Co's current Enterprise Value is ¥7,561 Mil.
Sirio Pharma Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥402 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sirio Pharma Co  (SZSE:300791) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sirio Pharma Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=36.13/1.743
=20.73

Sirio Pharma Co's share price for today is ¥36.13.
Sirio Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.743.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Sirio Pharma Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sirio Pharma Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sirio Pharma Co (SZSE:300791) Business Description

Traded in Other Exchanges
N/A
Address
No. 83, Taishan Road, Guangdong Province, Shantou, CHN, 515057
Sirio Pharma Co Ltd is engaged in the research and development, production, sales and technical services of nutrition and health food, food production, sales, import and export of goods.
Executives
Zheng Li Qun Directors, executives
Yang Rui Directors, executives

Sirio Pharma Co (SZSE:300791) Headlines

No Headlines